Because it degrades in blood in a pathway involving amino-peptidases, it may not be suitable for people who take medications that inhibit or are metabolized by peptidases (e.g., captopril, a treatment for hypertension).4 Also, based on what we know about other therapeutic peptides, we would say DSIP is contraindicated for women who are pregnant or breastfeeding as well as people with a personal history of cancer
Inflammation Control: BPC-157 may help modulate the inflammatory response, promoting faster recovery from exercise or injury
Jackie Jorkerson Person We've treated 1,400 firefighters with nebulized glutathione and continue to work with Pasadena Fire, Long Beach Fire and LAFD Station 69 in the Palisades
We encourage optimal glutathione levels through targeted injections and IVs, to help protect and enhance the cells most critical to fertility, while also preserving other key antioxidants within the body
Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population